Next-generation CAR-T therapy for malignant brain tumors: latest updates from the 2026 AACR Annual Meeting
Findings support mechanism-informed CAR T-cell platforms, while emphasizing that durability, neurotoxicity, trafficking, immunogenicity, and patient selection require validation in larger clinical studies.